Package Leaflet: Information for the Patient
AYVAKYT 25 mg film-coated tablets
avapritinib
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
What is AYVAKYT
AYVAKYT is a medicine that contains the active substance avapritinib.
What is AYVAKYT used for
AYVAKYT is used to treat adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL), after receiving at least one prior systemic treatment. These are disorders in which the body produces too many mast cells, a type of white blood cell. Symptoms occur when too many mast cells enter various organs of the body, such as the liver, bone marrow, or spleen. These mast cells also release substances, such as histamine, that produce various general symptoms that you may have, in addition to damaging the organs in question.
Together, ASM, SM-AHN, and MCL are referred to as advanced systemic mastocytosis (ASM).
How AYVAKYT works
AYVAKYT inhibits the activity of a group of proteins in the body called kinases. The mast cells of patients with ASM often undergo changes (mutations) in the genes involved in the production of specific kinases associated with the growth and spread of these cells.
If you have any questions about how AYVAKYT works or why this medicine has been prescribed for you, ask your doctor.
Do not take AYVAKYT
if you are allergic to avapritinib or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before starting treatment with AYVAKYT:
Be careful with this medicine:
While taking avapritinib, your doctor will ask you to have regular blood tests. You will also be weighed regularly.
See section 4 for more information.
Children and adolescents
AYVAKYT has not been studied in children and adolescents under 18 years of age. This medicine should not be given to children or adolescents under 18 years of age.
Other medicines and AYVAKYT
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, AYVAKYT may affect the way other medicines work, and some other medicines may affect the way this medicine works.
Tell your doctor or pharmacist before taking AYVAKYT if you are taking any of the following medicines:
The following medicines may increase the effects of avapritinib and may increase its side effects:
The following medicines may reduce the effects of avapritinib:
This medicine may affect the way the following medicines work or increase their side effects:
Ask your doctor or pharmacist before taking any medicine.
Using AYVAKYT with food and drinks
Do not drink grapefruit juice or eat grapefruit during treatment with AYVAKYT.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
This medicine is not recommended during pregnancy, unless clearly necessary. Avoid becoming pregnant while receiving treatment with this medicine, as it may harm the unborn baby. Your doctor will discuss with you the possible risks of taking AYVAKYT during pregnancy.
Your doctor may check if you are pregnant before you start treatment with this medicine.
Women of childbearing age must use effective contraceptive methods during treatment and for at least 6 weeks after finishing treatment. Male patients with female partners of childbearing age must use effective contraceptive methods during treatment and for at least 2 weeks after finishing treatment. Talk to your doctor about effective contraceptive methods that may be suitable for you.
Breastfeeding
Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if AYVAKYT passes into breast milk. Do not breastfeed while taking this medicine and for at least 2 weeks after the last dose. Talk to your doctor about the best way to feed your baby during this period.
Fertility
AYVAKYT may cause fertility problems in men and women. Ask your doctor for advice if this worries you.
Driving and using machines
AYVAKYT may cause symptoms that affect your ability to concentrate and react (see section 4). Therefore, AYVAKYT may affect your ability to drive and use machines. Be careful when driving a car or using machines if you experience these side effects.
AYVAKYT contains sodium.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist again.
What concentration of AYVAKYT to use
The recommended dose of AYVAKYT will depend on your disease: see the information below. AYVAKYT is available in tablets of different concentrations. These concentrations are 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg. Your doctor will advise you on the concentration and number of tablets to take.
Treatment of ASM
The recommended dose is 200 mg orally once daily.
If you have liver problems, your doctor may start your treatment with a lower dose of AYVAKYT.
If you experience side effects, your doctor may change your dose, temporarily interrupt, or permanently stop treatment. Do not change your dose or stop taking AYVAKYT unless your doctor tells you to.
Swallow the AYVAKYT tablet(s) whole with a glass of water, on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking AYVAKYT.
If you vomit after taking a dose of AYVAKYT, do not take an additional dose. Take the next dose at your scheduled time.
If you take more AYVAKYT than you should
If you have taken too many tablets accidentally, talk to your doctor immediately. You may need medical attention.
If you forget to take AYVAKYT
If you miss a dose of AYVAKYT, take it as soon as you remember, unless your next scheduled dose is within 8 hours. Take the next dose at your scheduled time. Do not take a double dose within 8 hours to make up for missed doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
More serious side effects
Some side effects can be serious. Tell your doctor immediately if you experience any of the following(see also section 2):
Other side effects may include:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice that the blister is damaged or shows signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
AYVAKYT Composition
Product Appearance and Packaging Contents
AYVAKYT 25 mg film-coated tablets are white and round, 5 mm in diameter, with the text "BLU" engraved on one side and "25" on the other.
AYVAKYT is supplied in a bottle with 30 film-coated tablets. Each box contains one bottle.
Keep the desiccant in the bottle.
Marketing Authorization Holder and Manufacturer
Blueprint Medicines (Netherlands) B.V.
Gustav Mahlerplein 2
1082 MA Amsterdam
Netherlands
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium, Czech Republic, Denmark, Germany, Estonia, Spain, France, Croatia, Ireland, Iceland, Italy, Latvia, Lithuania, Luxembourg, Hungary, Malta, Netherlands, Norway, Austria, Poland, Portugal, Romania, Slovenia, Slovakia, Finland, Sweden, United Kingdom (Northern Ireland) Blueprint Medicines (Netherlands) B.V., NL Tel: +31 85 064 4001 Email: MedinfoEurope@blueprintmedicines.com | Greece, Cyprus Swixx Biopharma S.M.S.A. Tel: +30 214 444 9670 |
Date of Last Revision of this Leaflet:
This medicinal product has been authorized with a "conditional approval". This type of approval means that more information is expected to be obtained for this medicinal product.
The European Medicines Agency will review the new information for this medicinal product at least once a year, and this leaflet will be updated as necessary.
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.